Navigation Links
Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM152, the Company's oral selective antagonist of the LPA1 receptor.  Completion of this study positions Amira to initiate a Phase 2a study in patients suffering from systemic sclerosis, a systemic fibrotic disease, by early 2012.

"The Phase 1 clinical study in healthy volunteers demonstrated that AM152 is safe and well-tolerated at doses which are expected to provide a full range of receptor coverage in humans," said Isabelle DeArmond, Vice President, Clinical Development. "These results enable us to study AM152 at a wide range of doses in patients suffering from fibrotic diseases."

Bob Baltera, Chief Executive Officer, added, "Initiating a Phase 2a study in patients suffering from systemic sclerosis will be an important milestone for the team at Amira; we look forward to better understanding the potential therapeutic benefit of AM152."

AM152 is a novel LPA1 receptor antagonist developed by the scientists at Amira.  Preclinical data has demonstrated that antagonism of the LPA1 receptor inhibits fibrosis in several disease models.  Much of these data has been previously presented and published by Amira scientists and colleagues.  Amira Pharmaceuticals also recently announced that AM152 was granted Orphan Drug Status by the FDA for patients suffering from idiopathic pulmonary fibrosis (IPF).

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
2. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
3. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
4. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
5. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
6. Visage Imaging Releases Amira 5.3
7. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
8. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
9. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013  Grifols, ein globales Unternehmen der ... , Spanien, präsentierte die Ergebnisse einer ... von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des ... ein Niveau anhebt, das innerhalb des für ... ist eine lebensbedrohliche, genetische Erkrankung, bei der ...
(Date:5/22/2013)... Israel , May 22, 2013 /PRNewswire/ ... leading developer and provider of microRNA-based molecular diagnostics, announces ... and Chief Executive Officer of Rosetta Genomics, will deliver ... taking place from June 3-6, 2013 in New York ... June 4 th at 2:00 p.m. Eastern time. ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... June 21 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, presented clinical data and analysis from ... patients with type 2 diabetes mellitus at ENDO 2010 today. ... of increased total GLP-1 in both LX4211 treatment arms relative ...
... 21 Reportlinker.com announces that a new market research report is available ... Global Coronary ... , , ... , , ...
Cached Medicine Technology:Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 2Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 3Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes 4Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 11Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 12Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 13Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 14Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 15Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 16
(Date:5/22/2013)... (PRWEB) May 22, 2013 Hosted by ... Cares free dental clinic provided more than $1.6 million ... May 18-19 in San Jose. , The California ... the clinic to provide free dental services and oral ... This is the third clinic held by CDA and ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Anyone ... is something about feet that fungi seem to like. ... the fungal groups that live on your skin -- ... It,s no secret that the human body is ... fungi, both outside and inside. And it,s mainly a ...
(Date:5/22/2013)... 2013 Successful Therapy for Parents ... Psychotherapy in the Silver Lake community of Los ... as progression to existing Parents and Couples counseling ... parenting therapy has always been suggested, but now ... now specializes in all aspects of relationships ...
(Date:5/22/2013)... 22, 2013 According to a May 14, ... More Options for Breast Cancer Surgery,” modern medical technology has ... approach this disease in a whole new light. Since the ... now face breast cancer and mastectomies with greater ... “Before the introduction of plastic surgery to oncology, women had ...
(Date:5/22/2013)... Researchers in genomic health disparities from the University of ... School of Medicine have teamed up to hold the ... Health Disparities in Genomic Medicine." The theme of ... business and government to reduce these disparities. , Despite ... States, individuals within underserved groups continue to be more ...
Breaking Medicine News(10 mins):Health News:Two-day San Jose Dental Clinic Provides More Than $1.6 Million in Care 2Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2
... health system of southern Australian hospitals has been graded at ... surgery admissions //and waiting times. ,This rating has ... recorded the second highest number of beds per capita in ... for every 1000 in population. ,Health Minister Tony ...
... New South Wales in Australia have developed a "super ... diabetes//, heart disease, arthritis and cancer. The drug, Dz13, ... aging as well, the researchers claimed. ,Also diseases like ... in a paper published in the latest issue of ...
... Pharma today said it has recieved a tentative New ... product used for treating HIV-1 infection//. ... drug product containing Lamivudine, Zidovudine, Nevirapine tablets used in ... Bombay Stock Exchange., ,The three drugs would now ...
... have discovered a method to cease the blood supply to ... cancer//. This, if proved conclusively, will infuse a new lease ... a protein, discovered while conducting a research on fruits, is ... them naturally. , ,The researchers said “By blocking the ...
... members and villagers, a woman who lost her husband to AIDS ... Bihar home. ,Premila Devi, 40, from Tilaei village in ... just a few months after her husband Sunil Mahto died of ... members as well as villagers treated her after her husband's death," ...
... determination test kits to counter online threats to its skewed ... Home DNA gender testing kit' for $275 promising results within ... unborn girls in Punjab, Haryana and Delhi. ,"We ... Health Minister Ramesh Chander Dogra told a news channel Sunday. ...
Cached Medicine News:Health News:South Australian health System In The Bottom Of Rankings 2
... Quality EEG recording is assured even ... Neurofax has high performance, high sensitivity ... ECG rejection filter, shielded electrodes and a ... connection. Neurofax is a complete and ...
... MagPro is the high performance magnetic stimulator ... in medical research. , ,MagPro is able to ... precise studies of the field/nerve interface can be ... biphasic waveform and coil-current direction. , , , ...
... is a new top-line range of digital ... Atrial Fibrillation (AF). Because the T-series combines ... the treatment of AF is taken one ... the heart rhythm is monitored continuously and ...
... MAX Cooling Power, Deeper Lesions ... arrhythmias, including atrial flutter, Freezor MAX is ... catheter with an 8mm ablation tip was ... is connected to the same cryoconsole as ...
Medicine Products: